1-13. (canceled)
14. A low dose oral pharmaceutical composition of isotretinoin comprising about 16 mg of isotretinoin, wherein the composition exhibits bioequivalence to a 20 mg formulation of Roaccutane upon administration to a human subject, wherein the bioequivalence is established by a 90% confidence interval for AUC0-\u221e which is between 80% and 125% upon administration with a continental breakfast.
15. The low dose oral pharmaceutical composition of claim 14, wherein the composition further comprises at least a first and a second lipidic excipient, wherein the first lipidic excipient has a HLB value equal to or greater than 10.
16. The low dose oral pharmaceutical composition of claim 15, wherein the first lipidic excipient is selected from the group consisting of glyceroyl macrogolglycerides, polyethylene glycol esters, and mixtures thereof.
17. The low dose oral pharmaceutical composition of claim 15, wherein the second lipidic excipient is selected from the group consisting of vegetable oils, medium chain triglycerides, fatty acid esters, glycerol oleate and mixtures thereof.
18. The low dose oral pharmaceutical composition of claim 15, wherein the first lipidic excipient comprises between 20% to 80% ww of the composition and the second lipidic excipient comprises between 5% to 70% ww of the composition.
19. The low dose oral pharmaceutical composition of claim 15, wherein the first lipidic excipient has a HLB value of at least 12.
20. The low dose oral pharmaceutical composition of claim 15, wherein the first lipidic excipient has a HLB value of at least 13.
21. The low dose oral pharmaceutical composition of claim 14, wherein the composition comprises a semi-solid partly in suspension and partly in solution of isotretinoin.
22. The low dose oral pharmaceutical composition of claim 21, wherein the composition comprises a semi-solid suspension of isotretinoin.
23. The low dose oral pharmaceutical composition of claim 21, wherein the composition comprises a semi-solid solution of isotretinoin.
24. The low dose oral pharmaceutical composition of claim 15, which further comprises at least one surfactant.
25. The low dose oral pharmaceutical composition of claim 24, wherein the surfactant is selected from the group consisting of sorbitan fatty acid esters, polysorbate compounds, polyoxyethylene sorbitan fatty acids esters, sodium lauryl sulphate, compounds of lecithin, propylene glycol esters, fatty acid esters of propylene glycol, fatty acid esters of glycerol, and mixtures thereof.
26. The low dose oral pharmaceutical composition of claim 24, wherein the surfactant comprises between 1% to 10% ww of the composition.
27. The low dose oral pharmaceutical composition of claim 15, which further comprises at least one disintegrant.
28. The low dose oral pharmaceutical composition of claim 27, wherein the disintegrant is selected from the group consisting of crosspovidone, sodium croscarmellose, and mixtures thereof.
29. The low dose oral pharmaceutical composition of claim 14, wherein the composition comprises from about 10 mg to 20 mg of isotretinoin.
30. The low dose oral pharmaceutical composition of claim 29, wherein the composition comprises from about 16 mg to 20 mg of isotretinoin.
31. The low dose oral pharmaceutical composition of claim 30, wherein the composition comprises 16 mg of isotretinoin.
32. The low dose oral pharmaceutical composition of claim 14, wherein the composition is in the form of a capsule.
33. The low dose oral pharmaceutical composition of claim 14, wherein the composition is in the form of a capsule.
34. An oral pharmaceutical composition of isotretinoin, wherein the composition exhibits an AUC0-\u221e 90% confidence interval comprised between 96% and 150% when compared to the same dosage strength of isotretinoin from Roaccutane after administration with a continental breakfast.
35. The oral pharmaceutical composition of claim 34, wherein the composition further comprises at least a first and a second lipidic excipient, wherein the first lipidic excipient has a HLB value equal to or greater than 10.
36. The oral pharmaceutical composition of claim 31, wherein the first lipidic excipient is selected from the group consisting of glyceroyl macrogolglycerides, polyethylene glycol esters, and mixtures thereof.
37. The oral pharmaceutical composition of claim 31, wherein the second lipidic excipient is selected from the group consisting of vegetable oils, medium chain triglycerides, fatty acid esters, glycerol oleate and mixtures thereof.
38. The oral pharmaceutical composition of claim 31, wherein the first lipidic excipient comprises between 20% to 80% ww of the composition and the second lipidic excipient comprises between 5% to 70% ww of the composition.
39. The oral pharmaceutical composition of claim 31, wherein the first lipidic excipient has a HLB value of at least 12.
40. The oral pharmaceutical composition of claim 31, wherein the first lipidic excipient has a HLB value of at least 13.
41. The oral pharmaceutical composition of claim 34, wherein the composition comprises a semi-solid partly in suspension and partly in solution of isotretinoin.
42. The oral pharmaceutical composition of claim 41, wherein the composition comprises a semi-solid suspension of isotretinoin.
43. The oral pharmaceutical composition of claim 41, wherein the composition comprises a semi-solid solution of isotretinoin.
44. The oral pharmaceutical composition of claim 35, which further comprises at least one surfactant.
45. The oral pharmaceutical composition of claim 44, wherein the surfactant is selected from the group consisting of sorbitan fatty acid esters, polysorbate compounds, polyoxyethylene sorbitan fatty acids esters, sodium lauryl sulphate, compounds of lecithin, propylene glycol esters, fatty acid esters of propylene glycol, fatty acid esters of glycerol, and mixtures thereof.
46. The oral pharmaceutical composition of claim 44, wherein the surfactant comprises between 1% to 10% ww of the composition.
47. The oral pharmaceutical composition of claim 35, which further comprises at least one disintegrant.
48. The oral pharmaceutical composition of claim 45, wherein the disintegrant is selected from the group consisting of crosspovidone, sodium croscarmellose, and mixtures thereof.
49. The oral pharmaceutical composition of claim 34, wherein the composition comprises from about 10 mg to 20 mg of isotretinoin.
50. The oral pharmaceutical composition of claim 56, wherein the composition is in the form of a capsule.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An electronic device comprising:
processing circuitry configured to
produce an audio sound from a virtual sound source position;
acquire from a user-input a sound position information of a perceived sound source position; and
control an enable or disable of a function of the electronic device based on a relationship between the virtual sound source position and the perceived sound source position.
2. The electronic device of claim 1, wherein
the processing circuitry is further configured to determine whether to enable or disable the function.
3. The electronic device of claim 1, wherein
the processing circuitry being a single CPU that performs processing to determine whether to enable or disable the function.
4. The electronic device of claim 1, wherein
the virtual sound source position is generated based on a head-related transfer function, HRTF.
5. The electronic device of claim 4, wherein
the HRTF is user-specific, and includes
a right function HRTF_R that depends on the user U, moving radius r, and deflections angles theta and phi, and expressed as HRTF_R(U, r, theta, phi), and
a left function HRTF_L expressed as LRTF_L(U, r, theta, phi).
6. The electronic device of claim 5, wherein
the processing circuitry is configured to produce a head-related impulse response, HRIR, by performing an inverse discrete Fourier transform on the HRTF.
7. The electronic device of claim 6, wherein
the HRIR having a left component expressed as HRIR_L(U, r, theta, phi) and a right components expressed as HRIR_R(U, r, theta, phi).
8. The electronic device of claim 7, wherein the processing circuitry is configured to produce the audio sounds as
an output acoustic signal to a left ear of the user, YL, and
an output acoustic signal a right ear of the user YR, wherein YL and YR are generated by a convolution, *, of HRIR_L(U, r, theta, phi), and HRIR_R(U, r, theta, phi) with an original sound X according to
YL=X*HRIR\u2014L(U, r, \u03b8, \u03c6) \u2003\u2003(Equation 1)
YR=X*HRIR\u2014R(U, r, \u03b8, \u03c6) \u2003\u2003(Equation 2).
9. The electronic device of claim 1, further comprising:
a head mounted display configured to be worn on a head of a user and having left and right speakers configured to produce sound in left and right ears of the user.
10. The electronic device of claim 1, wherein
the processing circuitry
selects the virtual sound source position from one of a plurality of different virtual sound source positions,
compares the virtual sound source position to the perceived sound source position information acquired from the user-input, and
controls the enable of the function of the electronic device when the processing circuitry determines that the perceived sound source position is a closer match to the virtual sound source position than any other of the plurality of different virtual source positions.
11. The electronic device of claim 10, wherein
the function is an unlock function that unlocks the electronic device for use.
12. The electronic device of claim 4, wherein
the HRTF is an average head-related transfer function of users having a common attribute.
13. The electronic device of claim 12,
the function is an unlock function that unlocks the electronic device for use.
14. The electronic device of claim 1, further comprising:
a head mounted display configured to be worn on a head of a user and having a display, wherein
the processing circuitry
selects the virtual sound source position from one of a plurality of different virtual sound source positions, and
displays indicia associated with the plurality of different virtual sound source positions.
15. The electronic device of claim 1, wherein
the processing circuitry is configured to move the virtual sound source position while the processing circuitry acquires the user-input for the sound position information for a plurality of perceived sound source positions.
16. The electronic device of claim 15, further comprising:
a line-of-sight input unit that identifies the user-input for the sound position information by tracking a line-of-sight of a user on a displayed image.
17. The electronic device of claim 1, wherein
the processing circuitry is configured to reproduce the audio sound of the virtual source corresponding to a user selectable attribute.
18. The electronic device of claim 1, wherein
the processing circuitry associates IDs for a plurality of different users,
the user-input also identifies a particular user from the plurality of different users, and
the function is an unlock function that unlocks the electronic device for use when and ID for the particular user is selected and there is a match between the virtual sound source position and perceived sound source position for that particular user.
19. An information processing method comprising:
producing with a speaker an audio sound from a virtual sound source position;
acquiring from a user-input interface a sound position information of a perceived sound source position; and
controlling with processing circuitry an enable or disable of a function of the electronic device based on a relationship between the virtual sound source position and the perceived sound source position.
20. A non-transitory computer readable storage medium having stored therein computer readable instructions that when executed by processing circuitry cause the processing circuitry to execute an information processing method, the method comprising:
producing with a speaker an audio sound from a virtual sound source position;
acquiring from a user-input interface a sound position information of a perceived sound source position; and
controlling with the processing circuitry an enable or disable of a function of the electronic device based on a relationship between the virtual sound source position and the perceived sound source position.